138 related articles for article (PubMed ID: 7504849)
1. Comparative analysis of fluctuation of serum tumor markers in advanced cancer of prostate.
Maatman TJ
Urology; 1993 Dec; 42(6):672-6. PubMed ID: 7504849
[TBL] [Abstract][Full Text] [Related]
2. The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
Maatman TJ
J Urol; 1989 Jun; 141(6):1378-80. PubMed ID: 2470927
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy.
Pontes JE; Jabalameli P; Montie J; Foemmel R; Howard PD; Boyett J
Urology; 1990 Nov; 36(5):415-9. PubMed ID: 1700527
[TBL] [Abstract][Full Text] [Related]
4. The role of serum prostatic acid phosphatase as a tumor marker in men with advanced adenocarcinoma of the prostate.
Maatman TJ; Gupta MK; Montie JE
J Urol; 1984 Jul; 132(1):58-60. PubMed ID: 6726962
[TBL] [Abstract][Full Text] [Related]
5. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N
J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Stamey TA; Kabalin JN
J Urol; 1989 May; 141(5):1070-5. PubMed ID: 2468794
[TBL] [Abstract][Full Text] [Related]
8. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
Mannini D; Maver P; Aiello E; Corrado G; Vecchi F; Bellanova B; Marengo M
Urol Res; 1988; 16(1):9-12. PubMed ID: 2449758
[TBL] [Abstract][Full Text] [Related]
10. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
11. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.
Shih WJ; Gross K; Mitchell B; Collins J; Wierzbinski B; Magoun S; Ryo UY
J Natl Med Assoc; 1992 Dec; 84(12):1049-50. PubMed ID: 1284282
[TBL] [Abstract][Full Text] [Related]
12. Use of serum markers in the diagnosis and management of laryngeal cancer.
Mevio E; Benazzo M; Galioto P; Spriano P; Pizzala R
Clin Otolaryngol Allied Sci; 1991 Feb; 16(1):90-2. PubMed ID: 2032368
[TBL] [Abstract][Full Text] [Related]
13. Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Nilsson B; Nordström L
Prostate; 1985; 6(3):285-91. PubMed ID: 3991370
[TBL] [Abstract][Full Text] [Related]
14. Critical assessment of prostate cancer staging.
Graham SD
Cancer; 1992 Jul; 70(1 Suppl):269-74. PubMed ID: 1376195
[TBL] [Abstract][Full Text] [Related]
15. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
Kraljić I; Kovacić K; Tarle M
Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
Stamey TA; Kabalin JN; Ferrari M
J Urol; 1989 May; 141(5):1084-7. PubMed ID: 2468796
[TBL] [Abstract][Full Text] [Related]
17. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
19. Prospective investigation of tumor markers and risk assessment in early cancer screening.
Kobayashi T; Kawakubo T
Cancer; 1994 Apr; 73(7):1946-53. PubMed ID: 8137222
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
